There is a large and rapidly growing unmet need for disease modifying drugs for Alzheimer’s disease. In 2015, the Alzheimer’s Association estimated that there were 5.3 million Americans with Alzheimer’s disease; by 2050 they estimate that this number will triple to 13.8 million. It is the sixth-leading cause of death in the industrialized world – and there is no cure.
Alzheimer’s disease pathology includes “plaques” of beta-amyloid and “tangles” of tau protein. These proteins tend to abnormally “clump”, and such protein misfolding processes give rise to inflammation and neuronal death. In order to make an impact on this disease, drugs must be found that can potently and selectively stop this process.